Analysis reveals distinct mutation patterns in myeloid malignancies, suggesting unique genetic features for AML and CML.
We performed an integrative analysis of molecular profiles of 52 patients with Myeloid malignancies from a tertiary care teaching hospital in Jaipur. Targeted next-generation sequencing of 80 genes revealed 23 genes mutated in over 5% of patients. Mutational profiles differed considerably from previous studies. FLT3, DNMT, NPM1, N-RAS, ASXL1, CEBPA and RUNX1 mutations were more frequent in AML patients, while CBL, JAK2, GATA2, SF3B1, WT1, KRAS, MPL, TP53 and ZRSR2 were less frequent. Additionally, we identified ABL gene in 2 CML, DNMT in 1 MDS, and IDH1, JAK2, MPL, EZH2, PDGFRA in MPN/MPN-PV.
No takes yet. Share an insight, caveat, or question.
Jaiswal et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: